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Abstract Lymphoproliferations associated with Epstein–
Barr Virus (EBV) in adult patients pose a diagnostic challenge
for pathologists for several reasons. First, the EBV
lymphoproliferations represent a clinically and histologically
very broad spectrum ranging from self- l imit ing
lymphoproliferations to manifest malignant lymphomas. Sec-
ond, the classification of these diseases is not solely based on
histopathology but rather requires a synopsis of clinical as
well as pathological features. And third, a resource-efficient
diagnostic procedure demands a deliberate strategy for
selecting the tissue specimens that are to be tested for EBV.
We describe how the clinical context and histological features
may indicate to histopathologists which lymphatic tissues
should be tested for the presence of EBV and how these
features guide the classification. We provide recommenda-
tions as to which biopsy specimens should be investigated
for EBVand which methods for detecting viral association are
appropriate.
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Introduction
The Epstein–Barr virus (EBV) was described by Michael
Anthony Epstein and Yvonne Barr, who isolated EBV virus
particles from endemic Burkitt lymphoma specimens [1].
EBV is a double stranded DNA virus of the herpes virus
family and is the most common virus affecting humans.
Exposure to EBVusually occurs during childhood. The infec-
tion occurs through oral transmission via saliva. By the age of
40, over 90 % of the world population has experienced an
EBV infection. EBV also plays a pathogenic role, mainly in
the deve lopment o f seve ra l T ce l l and B ce l l
lymphoproliferations (see below) but is also associated with
different types of rare epithelial and mesenchymal neoplasms
[2].
EBV is mainly a B-lymphotropic and epitheliotropic virus
and rarely infects T cells and NK cells. The life cycle of EBV
is composed of a lytic state and a latency state, the latter
allowing lifelong persistence of the virus in the host. The
replication cycle of EBV is composed of three phases: (i)
entry into either epithelial cells or naive B cells after oropha-
ryngeal transmission, (ii) lytic replication, and (iii) latency.
Once a cell has become infected, the viral capsid dissolves and
the DNA is transported into the cell nucleus. In epithelial cells,
the entry of EBV into the cell is usually directly followed by
the lytic replication of the virus, which leads to production of
infectious virions using the virus’s own replication machinery.
EBV persists in B cells throughout the differentiation from
naive B cells to germinal center cells to long-lived memory B
cells [2]. In memory B cells, no infectious virions are pro-
duced in the latency state. Dependent on the expression of
specific EBV-associated proteins and RNAs, three different
viral latency types have been described, which can be
reproduced to a certain extent by immunohistochemical
markers [2] (Table 1).
Primary infection by EBV—clinical and histological
features
Most humans become infected with EBV during childhood,
when the infection usually proceeds asymptomatically or with
mild symptoms that are undistinguishable from other viral
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infections. If the infection occurs in young adults and adoles-
cents, it can manifest as mononucleosis (glandular fever).
Primary EBV infection in adult patients is rare. Histologically,
pimary infection manifests in childhood or young adulthood
as ulcerative tonsillitis. Only occasionally are lymph nodes or
other sites affected. EBV tonsillitis differs from unspecific
tonsillitis related to other causes in its histologically detectable
polymorphic lymphoid infiltration with abundant
plasmablasts and occasional Hodgkin-like cells expanding in
the interfollicular area of the tonsils. In affected lymph nodes,
an extension of the interfollicular areas with a similarly poly-
morphic infiltration to that in tonsils can be observed. Within
the peripheral blood and bone marrow, CD8 positive lympho-
b las t s (Pfe i f fe r ce l l s ) migh t be observed . The
histomorphological picture of primary EBV infection shares
histomorphological features with other EBV-driven lympho-
proliferative diseases (LPD, Table 2). Therefore, the definite
diagnosis of infectious mononucleosis is based on the follow-
ing features: (i) young patient age, (ii) sole or main manifes-
tation in the tonsils, (iii) absence of immunosuppression in the
patient, and most importantly (iv) a serological test indicating
EBV primary infection (positive IgM titer).
Following the primary infection, patients become asymp-
tomatic virus carriers with a very limited number of EBV-
positive B cells. A tissue correlate of this phenomenon is the
occasional presence of single small EBV-encoded RNA
(EBER)-positive B cells, so called bystander cells, within
lymph nodes, mucosa-associated lymphatic tissue, or lungs.
Rare complications of primary EBV infection, such as the
chronic active EBV (CAEBV) disease and/or EBV-
associated hemophagocytic syndrome have recently been
reviewed in this journal [3].
Reactivation of EBV in adults
Since the vast majority of humans have been infected by
EBV in childhood and adolescence, EBV-associated LPDs
in adults usually arise from reactivation of the virus from
EBV-infected memory cells. Such reactivation is general-
ly considered to consist in an escape from the normal
immunosurveillance and preferentially occurs at sites
representing the physiological reservoir of EBV-infected
B cells, such as the lymphatic tissues and mucosa. There-
fore, EBV reactivation mainly occurs in immunocompro-
mised individuals. Elderly patients lacking clinically de-
tectable immunosuppression may also suffer from EBV
reactivation. In these patients, age-related decline in im-
munocompetence is assumed to be the cause of EBV-LPD
[4, 5]. Certainly, EBV reactivation does occasionally oc-
cur in patients lacking objectifiable immunodeficiency.
However, the diagnostic pathologist should stress that a
Table 1 EBV-latency types and expressed antigens
Latency type EBV-associated antigens
0/I EBER, EBNA1
II (default program) EBER, EBNA1, LMP1, LMP2B
III (growth program) EBER, EBNA1-6, LMP1, LMP2A+B
lytic all lytic antigens (e.g., ZEBRA)
Table 2 Spectrum of polymorphic EBV driven LPD with variable neoplastic potential
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clinical work-up of the immune status is warranted once
an EBV reactivation is detected.
EBV reactivation in adults occurs primarily in the form
of EBV-LPD presenting with a polymorphic histological
and clinical picture. Dependent on the clinical scenario
and the preferential site of involvement, different types of
polymorphic EBV-LPD can be distinguished. They are
outlined in Table 2 and include polymorphic posttrans-
plantation lymphoproliferations (PTLD) [6], EBV-positive
mucocutaneous ulcerat ion (EBVMCU) [7] , and
lymphomatoid granulomatosis [8]. Depending on the clin-
ical scenario and the extent of tissue involvement, these
conditions cause variable clinical symptoms. Polymorphic
EBV-LPD regress in most patients if immunocompetence
can be reestablished, e.g., by withholding immunosup-
pressive therapy. Nevertheless, a subgroup of polymor-
phic EBV-LPD progress to more aggressive diseases,
usually accompanied by a transformation to the morphol-
ogy of a fully developed lymphoma (designated as
“monomorphic” e.g., in the scenario of PTLD).
Polymorphic EBV-associated lymphoproliferations
share histomorphological and immunophenotypical fea-
tures, which are certainly not specific but should alert
the histopathologist to an EBV-driven disease when
Fig. 1 Histomorphology of EBV-associated lymphoproliferative dis-
eases. a and d illustrates the features of a primary EBV infection in the
oral mucosa of a child. As examples of EBV reactivation, an EBV-
associated mucocutaneous ulcer in the anal mucosa in a patient treated
with azathioprin for myastenia (b and e) and a lymphomatoid
granulomatosis in the lung of a patient (c and f) are shown. As shared
features in all lesions necrosis (arrow) and angiotropism (arrow head) are
indicated. All stainings Hematoxilin and Eosin, original magnification a–
c ×100, d–f ×400
Table 3 EBV-positive lymphomas and latency types and their association with immunocompromised state
Lineage Immunocompetence of patients Entity Latency type
B cell Competent Classical Hodgkin Lymphoma 2
Endemic Burkitt Lymphoma 0/1
Sporadic Burkitt Lymphoma 0/1
EBV+DLBCL of the elderly Variable
EBV+DLBCL associated with chronic inflammation (Pyothorax lymphoma) Predominantly 3
Compromised Primary effusion lymphoma 0/1
Plasmablastic lymphoma 0/1
Lymphomatoid Granulomatosis Grade 3 and DLBCL arising from the former 3
Monomorphic PTLDa Variable
Lymphomas associated with HIV infectiona Variable
Lymphoproliferative disease associated with primary immune disordersa Variable
Other iatrogenic immunodeficiency-associated lymphoproliferative disordersa 3
T cell Competent Angioimmunoblastic T cell lymphoma 0/1 or 2
Extranodal NK/T cell lymphoma 2
Compromised EBV-positive T cell lymphoproliferative disease of childhood and young adultsb Variable
a Diseases under this category are further specified according to histopathology
b The immunodeficiency in many of these young patients is postulated but not always objectifiable
DLBCL diffuse large B cell lymphoma, PTLD posttransplant lymphoproliferative disease
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& Angiotropic vasculitis-like lymphoid infiltrates
& Polymorphic picture rich in large cells, Hodgkin-like cells,
plasmablasts and plasma cells
& Intermingled large T cells (often CD8 positive)
& B blasts, with weak CD20 expression and expression
of CD30
If the clinical scenario (immunosuppression) or the histo-
logical features are suggestive of an EBV-LPD, testing by
EBER in situ hybridization should be initiated (see below).
When the diagnosis of an EBV-positive polymorphic LPD has
been confirmed by detection of EBV in the tissue, the nomen-
clature (classification) of the disease is dependent on (i) the
clinical context and (ii) the involved site (Table 2). There is
considerable overlap of histological and immunophenotypical
features between these “entities” (Fig. 1). For example, EBV-
LPD histologically resembling a lymphomatoid granulomato-
sis might occur after organ transplantation, in which case the
disorder is named according to both the clinical scenario and
the histopathological picture as “EBV-positive polymorphic
PTLD under the histopathological picture of a lymphomatoid
granulomatosis”. The most important diagnostic message
from the pathologist to the treating clinican should be (i) the
EBV association of the lesion and (ii) the clear distinction of
polymorphic EBV-LPD from fully developed lymphomas.
EBV-positive lymphomas
EBV-positive lymphomas occur in immunocompetent pa-
tients, but are much more frequent in immunocompromised
patients. In the latter patient group, the latency type of EBV
detectable in the lymphoma cells frequently but not exclusive-
ly indicates higher viral activity with expression of more EBV
encoded proteins (latency type 3) and sometimes active viral
replication. Lymphomas occurring in immunocompetent pa-
tients, such as Hodgkin lymphoma, usually display latency
types 0/1 or 2 with a more restricted pattern of EBV-associated
proteins and no viral replication (Table 3). The diagnostic
criteria for these lymphomas have been described elsewhere
and do not necessarily require the detection of EBV because
of the presence of EBV in the lymphoma cells. In rare cases,
detection of EBV is a mandatory diagnostic feature (e.g., in
EBV-positive LPD of childhood) [6]. Nevertheless, in certain
lymphoma entities, e.g., nasal and extranasal NK T cell lym-
phoma, angioimmunoblastic T cell lymphoma, primary effu-
sion lymphoma, and plasmablastic lymphoma, EBV associa-
tion remains an important clue towards the correct diagnosis.
Of further relevance might be the identification of EBV-
positive diffuse large B cell lymphoma (DLBCL) of the
elderly [9]. Histological features that are useful for identifying
DLBCL candidates for screening for EBV have been de-
scribed as angiotropic growth, necrosis, and polymorphic,
plasmablastic or Hodgkin-like differentiation and expression
of CD30 [6].
Distinguishing polymorphic EBV-LPD and EBV-positive
lymphoma
The diagnostic criteria for EBV-positive lymphomas are de-
scribed in the current WHO classification [6]. However,
distinguishing polymorphic EBV-LPD and a fully developed
EBV-positive lymphoma can be challenging. The most im-
portant feature, large sheets of EBV-positive blasts and ab-
sence of a polymorphic cellular picture, should raise suspicion
of an EBV-positive lymphoma, especially a DLBCL. A spe-
cifically difficult task is the differentiation of a polymorphic
EBV-LPD from a fully developed classical Hodgkin lympho-
ma, because the latter may be composed of a similarly poly-
morphic cellular infiltrate to that of the polymorphic EBV-
LPD. Table 4 shows helpful diagnostic features for separating
disorders. Pathologists should be aware of the fact that
Table 4 Differential diagnostic of polymorphic EBV-positive lymphoproliferative disease (LPD) compared to Hodgkin Lymphoma
Feature Hodgkin Lymphoma Polymorphic EBV+LPD
Histomorphology Mixed cellularity infiltration with Hodgkin (−like) cells, necrosis
Predominant epitheloid cells and eosinophils Predominant plasmablasts, plasmacells, angiotropism
Immunophenotype of large cells CD30>CD20 CD20>CD30
Expression of EBVantigens • EBER+cells equal to LMP1+cells
• EBER+large cells only
• EBNA2 negative
• EBER+cells more than LMP1+cells
• EBER+small and large cells
• EBNA2 +/−
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proteins expressed in Hodgkin lymphoma, such as CD15, can
also be observed in polymorphic EBV-LPD, like EBVMCU
[7], and therefore the final diagnosis will depend not only on
the histopathological features but also on the clinical context,
including the site of involvement. For example, Hodgkin
lymphomas rarely involve epithelial barrier organs, but
EBVMCU by definition always do (Table 2). In our experi-
ence, clonality testing is not helpful in differentiating EBV-
positive lymphoma from polymorphic lymphoproliferations,
as viral-driven LPD can also result in a clonal expansion of T
and B cells. Testing for EBNA2 expression is useful in some
cases, since expression of EBNA2 strongly argues against
Hodgkin lymphoma (Table 2).
Recommendations for EBV testing
The question as to which specimen should be tested for EBV
depends on the histopathological findings on the one hand and
on the clinical context on the other hand. Table 3 summarizes our
criteria and favored method of testing for EBV, fig. 2 shows
typical results. If pathologists are confronted with lymphoid
tissue histologically resembling inflammatory (reactive) tissue
in immunocompetent patients, the decision whether or not to test
for EBV is primarily based on histological features (Table 3). In
Fig. 2 An EBV-associated mucocutaneous ulcer in the colonic mucosa
(a Hematoxilin and Eosin). Staining pattern of EBV-encoded RNA
(EBER, b) is nuclear. The protein LMP1 is expressed in the cytoplasm
(c). EBNA2 protein expression is nuclear (d). Note the artificial cytoplas-
mic staining in the epithelium (d). The case illustrates the variability of
markers being detectable. EBER usually labels the majority of EBV-
infected cells, whereas LMP1 and EBNA2 if positive in the lesion stain
only a subset of all EBE-positive cells. Original magnification a–d ×400
Table 5 Recommendations for selecting tissue specimen and methods for EBV testing
Lymphoma Nodal and extranodal lymphatic tissue not presenting overt lymphoma (polymorphic
LPD)
Histopathological features Clinical context
Testing by EBER Testing by EBER Testing by EBER
B cell lymphomas




• Primary effusion lymphoma • Posttransplantation
• Pyothorax associated lymphoma
• DLBCL with histological features suspicious for EBV
association
• Necrosis • Drug induced
immunocompromised state• Angiotropism of blastic cells
• Any monomorphic PTLD
• Lymphomatoid granulomatosis • Plasmablastic infiltrate • HIV infection
T cell lymphomas
• AILT
• Extranodal NK/T cell lymphoma
• EBV-positive Tcell lymphoproliferative disease of childhood
and young adults
Testing by EBER or LMP
• Hodgkin Lymphoma
Testing by EBER, LMP1 and EBNA2
•Differential diagnosis between Hodgkin lymphoma and PTLD
PTLDposttransplantation lymphoproliferative disease, AITLangioimmunoblastic T cell lymphoma
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immunocompromised patients, EBV testing is useful in any
histologically inflammatory lesion. The method of testing should
be EBER in situ hybridization, which is most sensitive for
detecting EBV, especially in lesions that cannot necessarily be
expected to express other viral antigens such as LMP1 (Table 3).
Since indolent (low grade) B cell lymphomas are virtually never
associated with EBV, testing cannot be recommended. For other
entities, which are listed in Tables 3 and 5, testing should be part
of the standard diagnostic work-up. Immunohistochemical stain-
ing for LMP1 is sufficient for Hodgkin lymphoma, since these
lymphomas express the latency type 2. However, other lympho-
mas listed in Table 5, such as diffuse large B cell lymphomas,
require testing by EBER because LMP1 is frequently not
detectable.
Perspective
Although epidemiologic data are lacking, EBV-LPD distinct
from overt lymphoma will be increasingly recognized. This is
due on the one hand to the aging of many populations, with an
increase in age-associated EBV reactivation. On the other
hand, widespread access to commercial assays and automati-
zation leads to an increasing use of in situ hybridization for
EBER by diagnostic pathologists. Additionally, newly recog-
nized subgroups of lymphomas, such as the EBV-positive
DLBCL of the elderly, require the detection of EBV in more
lymphoma entities as part of the diagnostic process.
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